Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741080 | 0.96 | HTR6 (0.61) | HTR6CNR1MEN1HPGDKMT2A | |
| SCHEMBL6745779 | 0.92 | HTR6 (0.54) | HTR6CNR1 | |
| SCHEMBL6745657 | 0.90 | HTR6 (0.53) | HTR6CNR1SMN1; SMN2 | |
| SCHEMBL6746883 | 0.90 | HTR6 (0.71) | HTR6 | |
| SCHEMBL6744354 | 0.90 | HTR6 (0.66) | HTR6 | |
| SCHEMBL6744544 | 0.89 | HTR6 (0.72) | HTR6CNR1 | |
| SCHEMBL6745766 | 0.88 | HTR6 (0.58) | HTR6CNR1 | |
| SCHEMBL6741240 | 0.88 | HTR6 (0.61) | HTR6CNR1 | |
| SCHEMBL6744534 | 0.86 | HTR6 (0.59) | HTR6CNR1 | |
| SCHEMBL6743434 | 0.86 | HTR6 (0.56) | HTR6CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225065-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2003-12-04 | — | — | US | claimed |
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6579870-B2 | 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity | PHARMACIA & UPJOHN COMPANY | 2003-06-17 | — | — | US | claimed |
| EP-1294701-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020037892-A1 | Bis-arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | claimed |
| WO-2001098279-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| US-20040014966-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2004-01-22 | — | — | US | disclosed |
| US-20030225065-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-6586592-B2 | Labled isotopes of phenyl 4-(1,4-diazepin-1-yl)-2-amino phenyl sulfone derivatives used in nuclear magnetic resonance imaging and positron emission tomography | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-6579870-B2 | 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity | PHARMACIA & UPJOHN COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-1294701-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020115660-A1 | Bis -arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-20020037892-A1 | Bis-arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | disclosed |
| WO-2001098279-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PMP22, NLN, INA | HTR6 221/4885CNR1 20/4885MEN1 403/4885 |
| US-20020037892-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | HTR6 35/4885CNR1 118/4885MEN1 2530/4885 |
| US-20020115660-A1 | Bis -arylsulfones | PMP22, ARSA, CLN6 | HTR6 35/4885CNR1 118/4885MEN1 2530/4885 |
| US-20030225065-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | HTR6 35/4885CNR1 118/4885MEN1 2530/4885 |
| US-20040014966-A1 | Bis-arylsulfones | NPSR1, ARSA, SLC18A2 | HTR6 69/4885CNR1 11/4885MEN1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.